Bio-Techne Corp TECH
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TECH is a good fit for your portfolio.
News
-
BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS
-
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
-
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
-
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
-
BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS
-
BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES
-
BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA
-
BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM
Trading Information
- Previous Close Price
- $63.69
- Day Range
- $62.61–63.95
- 52-Week Range
- $51.79–89.91
- Bid/Ask
- $61.52 / $63.52
- Market Cap
- $9.98 Bil
- Volume/Avg
- 984,815 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 33.60
- Price/Sales
- 8.96
- Dividend Yield (Trailing)
- 0.50%
- Dividend Yield (Forward)
- 0.50%
- Total Yield
- 1.31%
Company Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 3,050
- Website
- https://www.bio-techne.com
Comparables
Valuation
|
Metric
|
TECH
|
TIHE
|
BIO
|
|---|---|---|---|
Price/Earnings (Normalized) | 33.60 | — | 23.22 |
Price/Book Value | 5.08 | — | 0.91 |
Price/Sales | 8.96 | — | 3.04 |
Price/Cash Flow | 31.28 | — | 10.06 |
Price/Earnings
TECH
TIHE
BIO
Financial Strength
|
Metric
|
TECH
|
TIHE
|
BIO
|
|---|---|---|---|
Quick Ratio | 2.54 | — | 4.01 |
Current Ratio | 4.37 | — | 5.83 |
Interest Coverage | 18.34 | — | −18.24 |
Quick Ratio
TECH
TIHE
BIO
Profitability
|
Metric
|
TECH
|
TIHE
|
BIO
|
|---|---|---|---|
Return on Assets (Normalized) | 11.61% | — | 2.73% |
Return on Equity (Normalized) | 15.75% | — | 3.84% |
Return on Invested Capital (Normalized) | 13.09% | — | 2.95% |
Return on Assets
TECH
TIHE
BIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fkwknkhnby | Dnmx | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pwjktrtj | Fbbnrnt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cgdbwwvy | Qssszj | $99.5 Bil | |
MRNA
| Moderna Inc | Htpmjdnt | Ssff | $38.8 Bil | |
ARGX
| argenx SE ADR | Rqvdgxck | Dqnv | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Dkymsvyt | Cfsw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tkxzjfrrb | Xwscbf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qkphqhsyr | Gfppqth | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pqmslctng | Gmsfns | $12.5 Bil | |
INCY
| Incyte Corp | Cnjlbnnz | Ghdqf | $11.6 Bil |